# Letter to the editor

# **Bacteremia or pseudobacteremia? Review of pseudomonas fluorescens infections**

Takeshi Nishimura<sup>1</sup>, Kenji Hattori<sup>1</sup>, Akihiko Inoue<sup>1</sup>, Taiji Ishii<sup>1</sup>, Tetsuya Yumoto<sup>2</sup>, Kohei Tsukahara<sup>2</sup>, Astunori Nakao<sup>2</sup>, Satoshi Ishihara<sup>1</sup>, Shinichi Nakayama<sup>1</sup>

<sup>1</sup> Hyogo Emergency Medical Center, 1-3-1 Wakinohamakaigando-ri, Chuo-ku, Kobe, Hyogo 651-0073, Japan

<sup>2</sup> Department of Emergency and Critical Care Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikatacho, Kitaku, Okayama City, Okayama, 700-8558, Japan

Corresponding Author: Takeshi Nishimura, Email: kogushi1@msn.com

### World J Emerg Med 2017;8(2):151–154 DOI: 10.5847/wjem.j.1920–8642.2017.02.013

# INTRODUCTION

*P. fluorescens* is an aerobic, Gram-negative bacillus related to *Pseudomonas aeruginosa*. Like other species of Pseudomonas, the organism is widespread in nature and is found in water, moist soil, and vegetation. Due to its low virulence, *P. fluorescens* is an infrequent cause of infections except for catheter-related bloodstream infections in cancer patients.

From August 1, 2003 to May 31, 2016, Hyogo Emergency Medical Center and the Kobe Red Cross Hospital treated three cases of bloodstream infection caused by *P. fluorescens*. Were these cases true bacteremia or pseudobacteremia? Would it be a risk to induce nosocomial infection, possibly leading to an infection outbreak? We retrospectively examined these three cases in detail.

We reviewed the database at the Hyogo Emergency

Medical Center and the Kobe Red Cross Hospital for cases of *P. fluorescens* bloodstream infection treated from August 2003 to May 2016. Baseline characteristics, basal disease, clinical course, laboratory data, use of blood-associated products, and laboratory examinations were retrospectively analyzed in these cases.

## RESULTS

Three patients who met these criteria and had *P. fluorescens* in their blood cultures were analyzed. Data was retrospectively collected from their medical records (Table 1).

### Case 1

A 77-year-old man with a history of esophageal carcinoma was admitted to the hospital complaining of esophageal stenosis. Parenteral nutrition support was started via a central venous catheter. On post-admission

Table 1. Medical record of the patients

METHODS

Patient	Diagnosis	Number of	Site of blood culture	Central	Antibiotics	Blood	Interval between	Date of
		positive blood culture		venous catheter		transfusion	blood transfusion and symptoms of infection	infection
77 M	Esophageal carcinoma CRT post operation	2/4	Percutaneous blood culture	For nutrition support	Cefozopran (5 days)	Non	Non	February 2013
83 M	Gastric cancer	4/4	Percutaneous blood culture	For peri- operative treatment	Cefmetazole (8 days) Ceftriaxone (5 days) Piperacillin (5 days)	RCC 8 units and colloid	9 and 7 days before	January 2013
39 F	Sub-arrachnoid hemorrhage	8/8	Percutaneous blood culture & culture of the catheter tip	For the treatment of sepsis	Meropenem (3 days) Ceftazidime (12 days)	RCC 2 units and colloid	Same day	March 2016

M: male; F: female; RCC: red blood cell concentration.

day five, he presented with severe malaise and chilliness. *P. fluorescens* was recovered from his blood culture. An antibiotic (cefozopran) was administered, and his conditions improved rapidly.

# Case 2

An 83-year-old man with gastric cancer underwent gastric resection. On post-operative day seven, he suddenly presented with chilliness and shivering. A central venous catheter was also placed to support parenteral nutrition. An antibiotic (cefmetazole) had already been administered in the perioperative period. *P. fluorescens* was recovered from his blood culture. Removal of the central venous catheter prevented exacerbation of his conditions. Afterwards, he recovered uneventfully.

## Case 3

A 39-year-old female was admitted to the hospital complaining of severe headache. She was diagnosed with subarachnoid hemorrhage due to rupture of an internal carotid-posterior communicating artery aneurysm. Emergent intracatheter treatment was performed to detect aneurysm rupture and embolize the vessels. Albumin and crystalloid were administered in the perioperative period. By post admission day 13, her vital signs had gradually deteriorated. Along with her exacerbating conditions, laboratory data was worsening. A central venous catheter was inserted on the same day. P. fluorescens was recovered in her blood culture on post admission day 15. An antibiotic (ceftazidime) was rapidly administered. No events occurred after recovery from septic shock. She was referred from the intensive care unit (ICU) to the neurosurgery department on post admission day 32.

According to the case 3 patient, *P. fluorescens* was detected from percutaneous blood culture and catheter tip. This result could fit the criteria of catheter-related bloodstream infection.<sup>[1]</sup>

## DISCUSSION

*P. fluorescens* is an aerobic Gram-negative bacillus related to Pseudomonas aeruginosa. This organism has an aspect as psychrophilic, therefore it can grow in refrigerated temperatures (4 °C) and use citrate as a carbon source for growth.<sup>[2]</sup> Like other members of the genus Pseudomonas, *P. fluorescens* is widespread in nature with a predilection for moist environments. *P. fluorescens* is considered as an infrequent cause of human infection

due to its low virulence and has been implicated mainly in pseudobacteremia outbreaks.<sup>[3,4]</sup> Immune-compromised patients with cancer are sometimes afflicted with infection. Because blood products are maintained in refrigeration for long periods of time, *P. fluorescens* can potentially cause critically severe problems. Scales et al<sup>[5]</sup> published a paper describing about the review of *P. fluorescens*. They described that most common site of *P. fluorescens* infection is the bloodstream, and most reported cases have been iatrogenic. Although most true blood transfusion-associated *P. fluorescens* bloodstream infections have been reported in the 1980s,<sup>[6–9]</sup> specific reports have not been published in recent decades, owing to high purification skills.

To our best knowledge, three reports of *P. fluorescens* infections among patients associated with intrinsically contaminated infusions,<sup>[10–14]</sup> and one report of an oncology patient from unknown origin<sup>[15]</sup> have been published. Gershman et al<sup>[12]</sup> and Benito et al<sup>[11]</sup> reported contaminated heparinized saline flush syringes and contaminated ice baths used to cool syringes for cardiac output determination in the cardiac care unit respectively. Wong et al<sup>[10]</sup> reported the spread of *P. fluorescens* derived from contaminated drinking water with bone marrow transplant patients. In the first published case associated with a *P. fluorescens* outbreak among cancer patients by Hsueh, the cause of infection and pathway of outbreak could not be determined.

Dalamaga et al<sup>[16]</sup> reported the first recorded case of infection with *P. fluorescens* strain, causing cutaneous abscess and recurrent bacteremia in a patient following a dog bite. *P. fluorescens* has also been reported to induce critical conditions such as endotoxic shock,<sup>[17]</sup> neonate sepsis,<sup>[18]</sup> meningitis,<sup>[19]</sup> and respiratory infections.<sup>[20]</sup> Although case reports of *P. fluorescens* bacteremia have been published, reports in recent decades have been rare.

Because of its low virulent infection, it is rare that *P. fluorescens* causes bacteremia leading to septic shock. Pseudobacteremia may be defined as the presence of bacteria in the blood culture in the absence of clinical or other bacteriologic evidence of bloodstream infection. Contaminations of blood culture may occur during venipuncture, in the preparation of culture media, or during laboratory processing of the culture. Contaminated lithium heparin bottles have also played a role as a source of pseudobacteremia due to *P. fluorescens*.<sup>[21,22]</sup>

All three of our cases were treated with central venous catheters and blood transfusion. While two had histories of cancer, one patient who suffered from subarachnoid hemorrhage had no compromised history. Although we suspected that pseudobacteremia might occur, P. fluorescens was detected again in blood culture after administration of antibiotics. They all presented with malaise and chilliness; therefore, antibiotic treatments were administered respectively. In all cases, clinicians could not examine the pathway of infection. In cases 1 and 2, we examined the result from medical records retrospectively. An outbreak could be suspected because the 2 cases did occur in January and February 2013. However, that could not be confirmed and pathways of infection were not clarified. In case 3, we suspect that the blood products used might have been related to septic shock due to P. fluorescens infection; thus, we made inquiries to the blood product's company regarding infection. However, there is no evidence that bacteria had grown from blood products. Unfortunately, inappropriate dealing of central venous catheter might contribute to blood stream infection. Contamination of organisms into the blood stream can induce sepsis even when the organism is low virulent in nature. As a result, we could not detect the source of infection.

*P. fluorescens* is rare, but might cause infection in patients with cancer or immune-suppression. Based on our experience, central venous catheters should also be considered as a risk of infection leading to sepsis. We should examine closely whether an infection is truly bacteremia or pseudobacteremia when *P. fluorescens* is recovered from blood culture. Furthermore, we had to survey the circumstances to detect the infectious pathway and prevent outbreaks if the infection was truly bacteremia in healthy patients.

We believe that all three of our cases were truly bacteremia because they presented infectious symptoms such as malaise, chilliness, and inflammation. Fortunately, outbreaks did not occur. When *P. fluorescens* is detected, we should detect the organism's infection pathway and consider potential infectious outbreaks in ICUs or cancer patient wards.

# CONCLUSION

Although *P. fluorescens* infections in recent decades have been rare due to clean blood products, the organism has the potential to induce sepsis, especially in patients with cancer or central venous catheters. We clinicians should be aware of these features when *P. fluorescens* is recovered in blood culture. Determining whether *P. fluorescens* is a true bacteremia or pseudobacteremia is important to prevent misunderstandings. Clinicians should reexamine the pathway of infection to prevent outbreaks if *P. fluorescens* has truly occurred.

# ACKNOWLEDGEMENT

Authors appreciate for the medical staff of the department of Hyogo Emergency Medical Center and the Department of Emergency and Critical Care Medicine at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences for improvement of this manuscript.

Funding: None.

**Ethical approval:** The study was approved by the Institutional Review Board.

**Conflicts of interest:** The authors declare there is no competing interest related to the study, authors, other individuals or organizations. **Contributors:** Nishimura T proposed the study and wrote the first draft. All authors read and approved the final version of the paper.

#### REFERENCES

- 1 Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45.
- 2 Pittman M. A study of bacteria implicated in transfusion reactions and of bacteria isolated from blood products. J Lab Clin Med. 1953;42(2):273–88.
- 3 Smith J, Ashhurst-Smith C, Norton R. *Pseudomonas fluorescens* pseudobacteraemia: a cautionary lesson. J Paediatr Child Health. 2002;38(1):63–5.
- 4 Simor AE, Ricci J, Lau A, Bannatyne RM, Ford-Jones L. Pseudobacteremia due to Pseudomonas fluorescens. Pediatr Infect Dis. 1985;4(5):508–12.
- 5 Scales BS, Dickson RP, LiPuma JJ, Huffnagle GB. Microbiology, genomics, and clinical significance of the *Pseudomonas fluorescens* species complex, an unappreciated colonizer of humans. Clin Microbiol Rev. 2014;27(4):927–48.
- Collignon P, Dreimanis D, Beckingham W. Pseudobacteraemia due to Pseudomonas fluorescens. J Hosp Infect. 1999;43(4):321– 2.
- 7 Murray AE, Bartzokas CA, Shepherd AJ, Roberts FM. Blood transfusion-associated *Pseudomonas fluorescens* septicaemia: is this an increasing problem? J Hosp Infect. 1987;9(3):243–8.
- 8 Khabbaz RF, Arnow PM, Highsmith AK, Herwaldt LA, Chou T, Jarvis WR, et al. *Pseudomonas fluorescens* bacteremia from blood transfusion. Am J Med. 1984;76(1):62–8.
- 9 Gibaud M, Martin-Dupont P, Dominguez M, Laurentjoye P, Chassaing B, Leng B. *Pseudomonas fluorescens* septicemia following transfusion of contaminated blood. Presse Med. 1984;13(42):2583–4.
- 10 Wong V, Levi K, Baddal B, Turton J, Boswell TC. Spread of *Pseudomonas fluorescens* due to contaminated drinking water in a bone marrow transplant unit. J Clin Microbiol. 2011;49(6):2093–6

- 11 Benito N, Mirelis B, Luz Galvez M, Vila M, Lopez-Contreras J, Cotura A, et al. Outbreak of *Pseudomonas fluorescens* bloodstream infection in a coronary care unit. J Hosp Infect. 2012;82(4):286–9.
- 12 Gershman MD, Kennedy DJ, Noble-Wang J, Kim C, Gullion J, Kacica M, et al. Multistate outbreak of *Pseudomonas fluorescens* bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy. Clin Infect Dis. 2008;47(11):1372–9.
- 13 Centers for Disease C, Prevention. Update: Delayed onset *Pseudomonas fluorescens* bloodstream infections after exposure to contaminated heparin flush—Michigan and South Dakota, 2005–2006. MMWR Morb Mortal Wkly Rep. 2006;55(35):961– 3.
- 14 Centers for Disease C, Prevention. Pseudomonas bloodstream infections associated with a heparin/saline flush—Missouri, New York, Texas, and Michigan, 2004–2005. MMWR Morb Mortal Wkly Rep. 2005;54(11):269–72.
- 15 Hsueh PR, Teng LJ, Pan HJ, Chen YC, Sun CC, Ho SW, et al. Outbreak of *Pseudomonas fluorescens* bacteremia among oncology patients. J Clin Microbiol. 1998;36(10):2914–7.
- 16 Dalamaga M, Karmaniolas K, Chavelas C, Liatis S, Matekovits H, Migdalis I. *Pseudomonas fluorescens* cutaneous abscess and recurrent bacteremia following a dog bite. Int J Dermatol.

2005;44(4):347-9.

- 17 Foreman NK, Wang WC, Cullen EJ Jr, Stidham GL, Pearson TA, Shenep JL. Endotoxic shock after transfusion of contaminated red blood cells in a child with sickle cell disease. Pediatr Infect Dis J. 1991;10(8):624–6.
- 18 Rais-Bahrami K, Platt P, Naqvi M. Neonatal pseudomonas sepsis: even early diagnosis is too late. Clin Pediatr (Phila). 1990;29(8):444.
- 19 Sarubbi FA Jr, Wilson B, Lee M, Brokopp C. Nosocomial meningitis and bacteremia due to contaminated amphotericin B. JAMA. 1978;239(5):416–8.
- 20 Thangkhiew I. Successful treatment with ceftazidime of a *Pseudomonas fluorescens* chest infection in a myasthenic patient. J Antimicrob Chemother. 1986;18(3):428–9.
- 21 Whyte A, Lafong C, Malone J, Golda BP. Contaminated lithium heparin bottles as a source of pseudobacteraemia. J Hosp Infect. 1999;42(4):342–3.
- 22 Namnyak S, Hussain S, Davalle J, Roker K, Strickland M. Contaminated lithium heparin bottles as a source of pseudobacteraemia due to *Pseudomonas fluorescens*. J Hosp Infect. 1999;41(1):23–8.

Received November 12, 2016 Accepted after revision March 5, 2017